Expert Interview
Discussing Axsome Therapeutics topline results of PARADIGM Phase 3 Trial of Solriamfetol in Major Depressive Disorder (MDD)
Ticker(s): AXSMInstitution: Stanford Medicine
Professor of Psychiatry at Stanford University and former Chair of the Department of Psychiatry and Behavioral Sciences from 1991 to 2010. He currently serves as Director of the Stanford Mood Disorders Center, focusing on advancing research and treatment in depression and related conditions.
Past President of the American Psychiatric Association and a leading authority on mood disorders and psychopharmacology, with significant contributions to understanding antidepressant mechanisms and glucocorticoid dysregulation.
Elected to the National Academy of Medicine and recipient of numerous prestigious awards; has authored hundreds of peer-reviewed publications and co-edits the Journal of Psychiatric Research.
Manages 200-300 patients with MDD
Describe your background and practice setting
Added By: nick_adminHow many patients with MDD do you currently manage?
Added By: nick_adminCan you describe the standard of care for MDD?
Added By: nick_adminWhere would Solriamfetol fit into your treatment algorithm for MDD?
Added By: nick_adminRank your excitement for Solriamfetol on a scale of 1-10
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
